Collecting Cancer Data: Central Nervous System

2014-2015 NAACCR Webinar Series August 6, 2015

NAACCR

Q&A

Please submit all questions concerning webinar content through the Q&A panel.

Reminder:

• If you have participants watching this webinar at your site, please collect their names and emails.

 We will be distributing a Q&A document in about one week. This document will fully answer questions asked during the webinar and will contain any corrections that we may discover after the webinar.



AGENDA

- Casefinding
- MP/H
- Quiz
- Anatomy
- Stage
- Treatment
- Quiz
- Case Scenarios

NAACCR

NAACCR

CASEFINDING



- Disease IndexPathology Reports
- Radiation Completion Summaries
- Cytology Reports



CASE ELIGIBILITY

- Includes <u>malignant & non-malignant</u> tumors <u>diagnosed</u> on or after 1/1/2004 of the following sites:
- Meninges (C70._)
- Brain (C71._)
- Spinal cord, cranial nerves, & other CNS (C72._)
- Pituitary gland (C75.1)
- Craniopharyngeal duct (C75.2)
- Pineal gland (C75.3)

TODAY WE WILL BE TOUCHING ON;

- Gliomas
- (PNET)Primitive Neuroectodermal tumors
- Meningiomas
- Primary Spinal Cord Tumors

NAACCR

TIP OF THE DAY!

Don't confuse these two acronyms....



TIP

Ppnet's are not the same as PNET's!

Ppnet's or (peripheral Primitive Neuroectodermal Tumor's): usually occur in the soft tissues of the chest, pelvis, and retroperitoneum and are rarely intracranial.

REPORTABLE TERMS

FORDS Case Eligibility & Overview of Coding Principles Section 1 page 3

Ambiguous Terms List Constituting a Reportable Diagnosis

- Tumor (Beginning with 2004 diagnosis and only for Sites C70.0-C72.9, C75.1-C75.3)
- Neoplasm Tumor (Beginning with 2004 diagnosis and only for Sites C70.0-C72.9, C75.1-C75.3)











NAACCR

MULTIPLE PRIMARY & HISTOLOGY RULES

- Based on the behavior of the tumor
- Malignant Meninges, Brain, Spinal Cord, Cranial Nerves, Pituitary gland, Craniopharyngeal duct and Pineal gland
- Benign and Borderline Intracranial and CNS
 Tumors



















NAACCR

Does Timing &/or laterality play a role in determining multiple primaries for malignant intracranial and CNS tumors







NAACCR 2014-2015 Webinar Series









SEQUENCING

• Records sequence of malignant and nonmalignant neoplasms over patient's lifetime.

4, 5, ?

- 00-59 and 99 for malignant and in situ behavior
- 00 = solitary malignant neoplasm
- 01 = first of multiple malignant neoplasms
- 60-88 for non-malignant behavior
- 60 = solitary non-malignant neoplasm · 61 = first of multiple non-malignant neoplasms

VAACCR

AND NOW A BRIEF PAUSE FOR ... AN EPI MOMENT

(insert the Bonanza theme song here)

NAACCR

REPORTING: BRAIN & CNS TUMORS

• First primary, clusters

- Malignant and non-malignant (2004+)
- Non-malignant causes disruption of normal function similar to malignant

Ø Acrom

- Location impacts survival
- Benign Brain Tumors Cancer Registries Amendment Act, Public Law 107-260 • 2002

• <u>CBTRUS</u>



EPIDEMIOLOGY: BRAIN & CNS TUMORS

- Non-malignant rates higher (11.0 per 100,000 versus 6.6) • Rates higher in women (13.8 per 100,000 versus 7.9)
- Malignant rates higher in developed countries Rates higher in men(7.8 per 100,000 versus 5.6)
- Survival varies significantly by age, behavior, & histology
- Pediatric survival a success story
 0-19 73% 5-year survival; 20-44 59%; 45-54 31%; 55-64 18%, 65-74 11%; 75+6% (malignant)
- Non-malignant survival higher in US than Europe
- 96% US 69-77 % Europe (adults)
 Glioblastoma lowest survival rates
- 4-17% 5-year survival dependent upon age

NAACCR

VAACCR

INCIDENCE, MORTALITY, TRENDS

- Analyzed as Brain & CNS; malignant Incidence 14th men, 2008-2012
- 7.8 per 100,000
 ↓1.4% annually
- Incidence 15th women, 2008-2012
 5.6 per 100,000
- ↓ 1.8% annually
- Mortality 11th men, 2008-2012 5.3 per 100,000
 stable

Mortality 10th women, 2008-2012
 3.5 per 100,000
 stable

ETIOLOGY/RISK FACTORS

Established risks

- Radiation exposure (Radiation therapy)
- Genetic disorders: Neurofibromatosis type 1 & 2, tuberous sclerosis, Von Hippel-Lindau disease, Li-Fraumeni
- Suspected risks
- Cell phone use (radiofrequency rays not ionizing radiation)
 Occupation exposures (vinyl chloride, petroleum products)
- Popular myths
- Sugar substitutes (aspartame)

EMF
 Some viruses





UNDERREPORTING

- Benign/Borderline brain tumors historically have high degree of inter-registry variability in rates
- Does the variability have public health importance or is it spurious?
- Prior investigation indicates benign/borderline brain tumors variability driven by case completeness differences

PILOT PROJECT OBJECTIVES Prior work indicates specific patient & tumor characteristics associated with underreporting for brain Non-microscopically confirmed, non-surgery • Younger age, Specific subsites Assess benign/borderline brain tumors variability by registry Survey high and low incidence registries Mutable differences in case ascertainment training, operations

- Assess correlations with rates
- Registry capacity, reporting facilities capacity, demographics, geography

VAACCR



NAACCR



- < % state funding</pre> • 100% Federal
- < % electronic sources
- Paper abstracting
- Physician office, pathology labs, stand-alone radiation facilities
- •>% reporting from local hospitals • versus cancer centers

SURVEY RESULTS: HIGHER INCIDENCE

- History of collection prior to 2004
- History of brain specific ascertainment training · 1 low registry had recent training
- History of issue
- Active case finding
- Radiation facilities Site-specific
- AIM software synoptic software
 Hospital discharge
- · Documented fewer case deletions during editing over time
- Knowledge of issues; prior self assessment
 Open ended questions—lists of potential barriers

VAACCR

SURVEY RESULTS: QUALITATIVE

- Open ended questions: extensive lists of barriers
- High
- Follow-back because brains are missed at facilities; delay-reporting (high)
- Radiology only cases
 Local hospitals; out of state centers
- Low
- "We don't get credit for those cases"
 "We have a back-log. We try to abstract all cases but if I have a malignant brain I will abstract that first."

NAACCR

CORRELATIONS RESULTS

No correlation

- # CoC hospitals; # NCI centers; # Pedi Oncology Groups
- Population size, Geographic area, Poverty, Rural
- Weak correlation
- % non-Hispanic black +
- Moderate correlation
- SEER registries +, Population Density +
- Strong correlation
 NAACCR Certification +

CONCLUSIONS

- Active case finding
- Linkage, use electronic sources
- Site Specific, code specific, patient discharge
 Non-Hospital sources
- Non-Hospito
 Radiology
- Kaalo
- Brain
- Active radiology case finding/hospital discharge
- Site specific
- AIM software

NAACCR

PUBLIC HEALTH RELEVANCE



- Collection ever more complex for all registries irrespective of funding level
- Important to determine specific methods that result in high levels of case ascertainment
- To effectively inform public health practice and research, we need to define and promulgate effective methods that can be adopted by all registries

ΑΝΑΤΟΜΥ	
ut trop	
VAACCA	45















LATERALITY

NAACCR

 $\mbox{-}\mbox{CNS}$ sites defined as paired for cases diagnosed 1/1/2004 and after

- Cerebral meninges C70.0
- Olfactory nerve C72.2
- Cerebrum C71.0
- Optic nerve C72.3
- Frontal lobe C71.1Temporal lobe C71.2
- Acoustic nerve C72.4Cranial nerve, NOS C72.5
- Parietal lobe C71.3
- Occipital lobe C71.4
 - Assign laterality as '0' for all other CNS sites



CEREBELLUM

- Vermis: narrow median portion of cerebellum between the 2 lateral hemispheres
- Lateral lobes: 2 lateral hemispheres of cerebellum; cranial and caudal
- Cerebellopontine angle: angle between cerebellum and pons

VAACCR









NAACCR 2014-2015 Webinar Series









WHO GRADE

- CNS tumor histologies are based on WHO grade as well as standard nomenclature.
- See page 596 of the AJCC Staging manual

QUESTION FOR KENDRA



How do we code histologic grade for a malignant brain tumor case where all we have is a WHO grade?

What about Anaplastic Astrocytoma, WHO grade III?

http://seer.cancer.gov/tools/grade/

What if the case is a benign tumor? Where do we code the WHO Grade?

VAACCR

STAGING

AJCC Summary Stage Collaborative Stage

VAACCR

AJCC STAGE

- Chapter 56 page 593
- No stage grouping
- Excellent background information
- Table 56.2 WHO classification of tumors of the central nervous system
- Table 56.3 WHO grades of CNS Tumors
- Brain Tumor Survival Data

NAACCR

AJCC STAGE

- Clinical Stage
- Pathologic Stage
- Clinical Staged by
- Pathologic Staged by
- TNM Edition
- 8 8

88

T88 N88 M88 Stage 88

T88 N88 M88 Stage 88

AJCC STAGE-88

- 88 is not an AJCC code
- Defined by FORDS as "Not Applicable"
- Defined by SEER as "Not applicable, no code assigned for this case in the current AJCC Staging Manual"
 The primary site and histology are not included in the about the statement of the chapter
- · Leukemia, CNS, malignancy of the medulla of the adrenal gland
- Lymphoma
- T88 N88 M88 Stage I, II, III, IV

NAACCR

SUMMARY STAGE 2000

- 1 Local
- Confined to: one hemisphere in one part of brain (infra/supratentorial); meninges; invading/encroaching on ventricular system
- 5 Regional
 crossing midline or tentorium invades bone, blood vessel, nerves, spinal cord
- 7 Distant Circulating cells in CSF; extension to nasal cavity, nasopharynx, posterior pharynx; outside CNS
- 8 Benign
- Codes 0, 2, 3, 4 are not applicable NAACCR

QUESTION FOR KENDRA



What Summary Stage should we assign a benign tumor of the brain?













COLLABORATIVE STAGE DATA COLLECTION SYSTEM (CSV02.05)

CNS SCHEMAS

Schema Name	Site Codes
Brain	C70.0, C71.0-C71.9
CNSOther	C70.1, C70.9, C72.0-C72.5, C72.8- C72.9
IntracranialGla nd	C75.1, C75.2, C75.3

NAACCR

NAACCR

OTHER CS DATA ITEMS FOR CNS SCHEMAS

- CS Tumor Size/Ext Eval = 9
- CS Lymph Nodes = 988
- CS Lymph Nodes Eval = 9
- Regional Nodes Positive = 99
- Regional Nodes Examined = 99
- CS Mets Eval = 9

CS EXTENSION: BRAIN • Code 050 • Benign or borderline • Codes 100-510 • Confined to brain or cerebral meninges • Supratentorial tumor • Infratentorial tumor • Crosses midline • Crosses tentorium cerebelli • Codes 600-800 • Extension beyond brain or cerebral meninges • 710: Circulating cells in CSF

CS METS AT DX: BRAIN

- 00: No distant metastasis
- 20: Drop metastasis
- 30: Metastasis outside the CNS (extra-neural)
- 50: 20 + 30
- •99: Unknown

NAACCR

SSF1: WHO GRADE CLASSIFICATION

- \cdot Histologic grading classification for CNS tumors by the WHO
- Important prognostic factor for response to treatment & outcomes for CNS tumors
- Not the same as ICD-O-3 grade/differentiation
- Coded in the SSF1

SSF1: WHO GRADE CLASSIFICATION

- Code WHO grade as documented in health record
- If WHO grade is not documented see Table 56.3 in AJCC 7th Ed. (page 596) for specific histologies with assigned WHO grade
- Examples:
- Anaplastic astocytoma grade III
- Glioblastoma grade IV
- Meningioma grade I

VAACCR

SSF1: WHO GRADE CLASSIFICATION

- Grade I: Code 010
- Slow-growing, nonmalignant
- Grade II: Code 020
- Slow-growing; can be nonmalignant or malignant
- Grade III: Code 030
 Malignant
- Grade IV: Code 040
- Very aggressive malignant tumors

NAACCR

SSF2: KI-67/MIB-1 LABELING INDEX (LI)

- Ki-67 is a nuclear protein
- Labeling index (LI)
- Record percentage of carcinoma cells in the tissue
- sample with positive IHC staining for Ki-67 protein
- Staining may be done with MIB-1 monoclonal antibody
- May correlate with patient's clinical course
- This can typically be found in the path report as the testing will be completed on tumor tissue.

SSF3: FUNCTIONAL NEUROLOGIC STATUS -KARNOFSKY PERFORMANCE SCALE (KPS)

0: Dead

 Record the KPS as documented by physician in patient's record

 Do NOT infer KPS from information in record

VAACCR

• Used to compare treatment effectiveness and to assess prognosis 10: Maribund 20: Very sick 30: Severely disabled 40: Disabled 50: Requires considerable assistance 60: Requires accasional assistance 70: Cares for self but unable to carry on normal activity 80: Normal activity with enfort 90: Normal activity with minor signs disease 100: Normal with no evidence of disease

SSF4: METHYLATION OF O6-METHYLGUANINE-METHYLTRANSFERASE (MGMT)

- MGMT is DNA repair enzyme
- Methylation shuts down DNA repair
- Increased methylation may allow specific drugs to be effective on CNS tumors



NAACCR

Typically listed on an addendum to a pathology report.





SSF8: UNIFOCAL VS. MULTIFOCAL TUMOR

- Record whether tumor is solitary or multifocal at time of diagnosis
- Multifocal tumors have a worse prognosis
- Affect treatment decisions

QUESTIONS?

NAACCR

TREATMENT

- Gliomas
- Anaplastic gliomas and glioblastoma multiforme
- Low grade infiltrative astrocytomas
- Oligodendroglioma
- Ependymomas
- (PNET) Primitive Neuroectodermal tumors
- Meningiomas
- Primary Spinal Cord Tumors

NAACCR

	TREATMENT C	of gliomas		
Grade	Example Histology & Behavior	Treatment #1	Treatment 2	Treatment #3
Low Grade I, II	Astrocytomas & Oligodendromas	Surgery Total gross resection Stereotactic biopsy Open biopsy Subtotal resection	Radiation	Watchful Waiting
High Grade III, IV	Anaplastic Oligodendromas & Glioblastoma	Surgery Total gross resection Subtotal resection Stereotactic or open biopsy	Radiation Therapy Standard adjuvant treatment after surgery	Chemotherapy Temozolomide PCV Carmustine wafers (intraoperative)
NAACCR				





- Surgery
 Total gross resection
 Stereotactic biopsy
- Open biopsy
 Subtotal resection
- Radiation

Watchful Waiting

TREATMENT OF HIGH GRADE GLIOMAS

High grade defined as WHO grade III or IV Example: Anaplastic Oligodendromas & Glioblastoma

- Surgery
 Total gross resection of the tumor
 Subtotal resection
- Stereotactic or open biopsy
- Radiation Therapy
 Standard adjuvant treatment after surgery
- Chemotherapy
- Temozolomide
 PCV
- Carmustine wafers (intraoperative)

VAACCR

	TREATMENT C	F EPENDYN	NOMAS	
Grade	Example Histology & Behavior	Treatment #1	Treatment 2	Treatment #3
I	Subependymoma (9383/1) Myxopapillary ependymoma (9394/1)	Observation if asymptomatic and tumor is less than 30mm	Gross total resection	Subtotal resection with a radiation if the tumor is more than 30mm
II	Ependymoma, nos (9391/3)	Observation if asymptomatic and tumor is less than 30mm	Gross total resection	Subtotal resection with adjuvant radiation
III	Anaplastic ependymoma (9392/3)	Gross total resection followed by radiation	If not a surgical candidate, radiation alone.	



TREATMENT OF PRIMITIVE NEUROECTODERMAL TUMORS (PNET)

Most Common Type: Medulloblastoma (Infratentorial) or Supratentorial, WHO Grade IV

- Surgery
- Gross total resection whenever possible
- Adjuvant radiation
- Adjuvant systemic treatment

REMEMBER THE TIP OF THE DAY!

Т	Reatment of I	MENINGIOMAS	5
Grade	Treatment #1	Treatment 2	Treatment #3
I	Observation Asymptomatic Tumor <30 mm	Surgery Symptomatic Surgical candidate Tumor >30mm	Radiation Tumor >30mm Non-surgical candidate
II	Observation Asymptomatic Tumor <30 mm	Surgery Symptomatic Surgical candidate Tumor >30mm	Radiation Tumor >30mm Non-surgical candidate
III	Surgery	Adjuvant radiation	
VAACCR			91

T	Reatment Rimary Sp	OF INAL CORD	TUMORS	
Grade	Examples	Treatment #1	Treatment 2	Treatment #3
I	meningiomas peripheral nerve sheath tumors	Observation if asymptomatic	Surgery if symptomatic	Radiation if symptoms persist after treatment
I	astrocytomas ependymomas		Gross total resect	lion
Grad	e II and higher		Partial resectio	n
NAACCR				92

	SURGERY CODES	
Code	Procedure	Specifics
20	Local excision of tumor, lesion or mass; excisional biopsy	Used when the surgeon describes the procedure "biopsy," or "excisional biopsy", or when there are no details about the procedure. Unknown whether total or partial tumor resected.
21	Subtotal resection of tumor, lesion or mass in brain	Near total, partial, subtotal, debulking, open biopsy (if residual tissue).
22	Resection of tumor of spinal cord nerve	
30	Radical, total, gross resection of tumor, lesion or mass in brain	The resection of the brain tissue surrounding the tumor is limited to ensure clean margins. THIS 30 code can be used with all cases regardless of diagnosis year.
40	Partial resection of lobe of brain, when the surgery cannot be coded as 20-30.	Less than lobectomy, but more than it would be necessary to ensure clean margins
55	Gross total resection	Lobectomy
NAACCR		



While abstracting a case you discover documentation stating that the patient underwent NeuroBlate Laser Interstitial Thermal Therapy to treat a glioblastoma of the frontal lobe of the brain. What surgery code you document in the surgery field?

NAACCR

Code	Specific Energy	Radiation Type	
20-30	Orthovoltage Cobalt Photons Electrons neutrons	External beam radiation	
31	IMRT Intensity modulated radiation therapy	External beam radiation	
32	3D conformal radiation	External beam radiation	

TREATMENT MODALITY

Radiosurgery

- Code 40: Particle or proton beam
- Code 41: Stereotactic radiosurgery NOS
- Code 42: Linac radiosurgery
- CyberknifeCode 43: Gamma knife





DON'T FORGET • To document follow-up imaging following a surgical resection. • You may need to review several due to the fact that post-surgical changes may obscure residual tumor identification. • To umay need to review several due to the fact that post-surgical changes may obscure residual tumor identification. • Worker Construction Construction of the fact that post-surgical changes may obscure residual tumor identification.

Quiz Case Scenarios	
QUESTIONS?	2

COMING UP...

- Coding Pitfalls
- •9/3/15
- New starts October 1st!
- Collecting Cancer Data: Unusual Sites and Histologies
 <u>http://www.naaccr.org/EducationandTraining/WebinarSeries.aspx</u>





CE CERTIFICATE QUIZ/SURVEY

- Phrase
- Glioma
- Link
- http://www.surveygizmo.com/s3/2260744/CNS